Clinical Trials Logo
  1. Home
  2. Kerato Conjunctivitis Sicca
  3. NCT03616899

Safety and Efficacy of KPI-121 in Subjects With DED — STRIDE 3  

Kerato Conjunctivitis Sicca Clinical Trial

Official title:
A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)

Clinical Trial Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

Clinical Trial Description

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03616899
Study type Interventional
Source Kala Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 3
Start date July 10, 2018
Completion date February 5, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT03878628 - Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease Early Phase 1
Completed NCT05825352 - PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms N/A
Active, not recruiting NCT05848128 - Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Phase 3
Completed NCT05807360 - PMCF Study to Evaluate Performance and Safety of "Hyaluronic Acid (HA)-Based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT05823961 - PMCF Study to Evaluate Performance and Safety of "CLHA-based Eyedrops" Used to Improve Lacrimal Abnormalities N/A
Completed NCT05119920 - Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease Phase 2
Terminated NCT06329687 - A Study Evaluating the Safety of the Nasal Pump Phase 4
Recruiting NCT03652415 - DRy Eye Outcome and Prescription Study
Completed NCT05825586 - PMCF Study to Evaluate Performance and Safety of "Distilled Waters-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A